1. Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients
   Xuan Zhou et al, 2020, Int J Hematol CrossRef
2. Six-gene signature for predicting survival in patients with head and neck squamous cell carcinoma
   Juncheng Wang et al, 2020, Aging CrossRef
3. High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia
   Chengliang Yin et al, 2021, Front. Oncol. CrossRef
4. Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies
   Livingstone Fultang et al, 2021, Front. Oncol. CrossRef
5. Establishment of Prognosis Model in Acute Myeloid Leukemia Based on Hypoxia Microenvironment, and Exploration of Hypoxia-Related Mechanisms
   Jinman Zhong et al, 2021, Front. Genet. CrossRef
6. The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
   Nidhi Jyotsana et al, 2022, Front. Oncol. CrossRef
7. Glutamatergic system components as potential biomarkers and therapeutic targets in cancer in non-neural organs
   Ana Cristina García-Gaytán et al, 2022, Front. Endocrinol. CrossRef
8. Investigation of distinct gene expression profile patterns that can improve the classification of intermediate-risk prognosis in AML patients
   Nasr Eshibona et al, 2023, Front. Genet. CrossRef
9. Identification of hub genes and potential molecular mechanisms related to drug sensitivity in acute myeloid leukemia based on machine learning
   Boyu Zhang et al, 2024, Front. Pharmacol. CrossRef
10. Clinicopathological characteristics of invasive stratified mucinous carcinoma of the cervix and the expression and clinical significance of SLC7A11, SLC3A2 and PD-L1
    Changyu Lu et al, 2024, Front. Oncol. CrossRef